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Objectives: To determine the prognostic significance of tissue stiffness measurement
using transrectal ultrasound shear wave elastography in predicting biochemical
recurrence following radical prostatectomy for clinically localized prostate cancer.
Patients and Methods: Eligible male patients with clinically localized prostate
cancer and extraperitoneal laparoscopic radical prostatectomy between November 2013
and August 2017 were retrospectively selected. Information of potential biochemical
recurrence predictors, including imaging (ultrasound shear wave elastography and
magnetic resonance imaging), clinicopathological characteristics, and preoperative
prostate specific antigen (PSA) levels were obtained. Recurrence-free survival (Kaplan–
Meier curve) and a multivariate model were constructed using Cox regression analysis
to evaluate the impact of shear wave elastography as a prognostic marker for
biochemical recurrence.
Results: Patients experienced biochemical recurrence in an average of 26.3 ±
16.3 months during their follow-up. A cutoff of 144.85 kPa for tissue stiffness
measurement was estimated for recurrence status at follow-up with a sensitivity of
74.4% and a specificity of 61.7%, respectively (p < 0.05). In univariate analysis, shear
wave elastography performed well in all preoperative factors compared to biopsy
Gleason Score, PSA and magnetic resonance imaging; in multivariate analysis with
postoperative pathological factors, shear wave elastography was statistically significant
in predicting postoperative biochemical recurrence, which improved the C-index of
predictive nomogram significantly (0.74 vs. 0.70, p < 0.05).
Conclusions: The study revealed that quantitative ultrasound shear wave
elastography-measured tissue stiffness was a significant imaging marker that
enhanced the predictive ability with other clinical and histopathological factors in
prognosticating postoperative biochemical recurrence following radical prostatectomy
for clinically localized prostate cancer.
Keywords: prostate cancer, radical prostatectomy, biochemical recurrence, ultrasound shear wave elastography,
nomogram
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INTRODUCTION
The primary goal of biomarker/predictive test research in the
field of prostate cancer (PCa) is to increase the prediction
rate of postoperative outcome and/or biochemical recurrence
(BCR). Radical prostatectomy (open or minimally invasive) is
an established treatment option for clinically localized PCa.
Thirty to forty percent of men show postoperative BCR and
require further adjuvant or salvage treatments on follow-up (1, 2).
Predicting recurrence would be useful in setting up personalized
TABLE 1 | Characteristics of recurrence and non-recurrence patients.
Total Recurrence Non-recurrence
No. of patients 209 45 164
Age (years), mean ± SD (range) 66 ± 4.92 (53–76) 66 ± 5.20 (59–76) 66 ± 4.87 (53–76)
Preoperative PSA level (ng/ml), mean ± SD (range) 11.26 ± 7.48 (0.1–47.7) 14.21 ± 9.81 (2–47.7) 10.49 ± 6.56 (0.1–47)
PSA density (ng/ml2), mean ± SD (range) 0.19 ± 0.15 (0.001–1.11) 0.26 ± 0.20 (0.05–1.11) 0.17 ± 0.12 (0.001–0.92)
Gleason score at biopsy
3+3 39 (18.7%) 4 (1.9%) 35 (16.7%)
3+4 76 (36.4%) 8 (3.8%) 68 (32.5%)
4+3 39 (18.7%) 8 (3.8%) 31 (14.8%)
3+5 7 (3.3%) 3 (1.4%) 4 (1.9%)
4+4 27 (12.9%) 9 (4.3%) 18 (8.6%)
4+5 17 (8.1%) 13 (6.2%) 4 (1.9%)
5+3 1 (0.5%) – 1 (0.5%)
5+4 3 (1.4%) – 3 (1.4%)
PI-RADS
Benign 8 (3.8%) 1 (0.5%) 7 (3.3%)
3 17 (8.1%) 1 (0.5%) 16 (7.7%)
4 45 (21.5%) 4 (2%) 41 (19.6%)
5 131 (62.7%) 35 (17%) 96 (45.9%)
N/I* 8 (3.8%) 4 (1.9%) 4 (1.9%)
Surgical margin
Negative 126 (60.3%) 11 (5.3%) 115 (55.0%)
Positive 81 (38.7%) 32 (15.3%) 49 (23.4%)
N/I 2 (1.0%) 2 (1.0%) –
Gleason Score after RP
3+3 5 (2.4%) – 5 (2.4%)
3+4 101 (48.3%) 2 (1.0%) 99 (47.4%)
4+3 34 (16.3%) 7 (3.3%) 27 (12.9%)
3+5 19 (9.1%) 7 (3.3%) 12 (5.7%)
4+4 3 (1.4%) – 3 (1.4%)
4+5 45 (21.5%) 27 (12.9%) 18 (8.6%)
N/I 2 (1.0%) 2 (1.0%) –
Vascular invasion
Negative 185 (88.5%) 31 (14.8%) 154 (73.7%)
Positive 16 (7.7%) 10 (4.8%) 6 (2.9%)
N/I 8 (3.8%) 4 (1.9%) 4 (1.9%)
Lymph node involvement
Negative 186 (89.0%) 32 (15.3%) 154 (73.7%)
Positive 10 (4.8%) 8 (3.8%) 2 (1.0%)
N/I 13 (6.2%) 5 (2.4%) 8 (3.8%)
*No information.
treatment plans for patients, as well as selecting men for adjuvant
treatment following prostatectomy. An improved method of
predicting recurrence can help in reducing overtreatment of PCa
recurrence and thereby reducing side effects and improve quality
of life.
There are several known predictors for BCR following surgical
therapy for PCa published in the literature, e.g., age, prostate
specific antigen (PSA), biopsy Gleason Score (bGS), clinical
stage, pathology Gleason Score (pGS), and other postoperative
data (3); however, ultrasound imaging, specifically ultrasound
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shear wave elastography (USWE), as imaging marker has not
been reported.
Ultrasound imaging has been widely applied to guide
transrectal and transperineal biopsies in the detection of PCa
(4–6). USWE estimation of prostate tissue stiffness has been
recently reported with promising diagnostic accuracy in both the
detection and characterization of PCa (7–9). We have recently
shown that the technology can reliably predict the grade of
cancer and may provide essential information on the biology and
microenvironment of the cancerous lesions. Moreover, USWE
showed a very high diagnostic accuracy in predicting clinically
significant PCa in men opting for radical prostatectomy (10, 11).
The aim of this study was to assess the predictive usefulness of
USWE measured tissue stiffness in postprostatectomy BCR.
MATERIALS AND METHODS
Study Population
Between November 2013 and August 2017, 212 consecutive
men opting for extraperitoneal radical prostatectomy as a
treatment option for clinically localized PCa were selected. This
was part of a prospective, protocol-driven study with prior
ethical and institutional approval [Research Ethical Committee
(REC) No. 13/ES/0099, and Research and Development No.
2012ON32] designed to assess the diagnostic accuracy of
transrectal SWE ultrasound specifically for PCa. The basic
demographic characteristics are presented in Table 1. Men were
followed up postoperatively in clinics with PSA measurements
every 3 months for the first year, 6-monthly for the second
FIGURE 1 | Examples of BCR and BCR-free patients in comparison of SWE and clinicopathology data.
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year, and once a year thereafter. A PSA of more than 0.2 ng/ml
was considered as a cutoff for consideration of BCR, and this
generated a request to discuss the case in multidisciplinary
meeting for imaging and adjuvant/salvage treatment. The patient
cohort was divided into two groups: BCR and BCR free groups
as illustrated in Figure 1. PSA follow-up was recorded until April
2019, and the minimum follow-up for the recruited patients was
21 months.
Clinicopathology Information
All clinical data [age, weight, preoperative PSA and relative
density (PSAD), PI-RADS score on multiparametric MRI
(mpMRI), bGS, USWE], postoperative data [pGS, surgical
margins (SM), seminal vascular invasion (SVI), lymph node
involvement (LNI)], and clinical follow-up (months) were
recorded. In all eligible patients, PSA fell to an undetectable
level (<0.1 ng/ml) postoperatively. BCR was defined as any two
consecutive PSA measurements ≥0.2 ng/ml detected during the
follow-up (12).
MR Protocol and PI-RADS Scoring
MRI scan for each patient was carried out 6–8 weeks after
the last biopsy with a 3-T scanner (TIM Trio, Siemens,
Erlangen, Germany) to eliminate the artifacts due to blood
clots caused by biopsy. Then, radical prostatectomy was
usually done within 2 months (62 days targets) after MRI
in this cohort. MRI protocol was derived from the European
Society of Uro-radiology Guidelines (ESUR) 2012 (13) for PCa
detection; acquisition parameters are shown and summarized
in Table 2 (10, 11). All MR images were analyzed and scored
by experienced uro-radiologists (SA, SMB) using PI-RADS
v2.0; patients’ clinicopathology data were blinded to both
radiologists. Only suspicious lesions with PI-RADS score 3
and above were marked. Some of the patients’ PI-RADS
scores were not available because of inadequate sequences or
poor images.
USWE Imaging Protocol and Acquisition
All USWE images were obtained using a transrectal endocavity
transducer (SuperSonic Imagine, Aix en Provence, France)
with patients being in either lithotomy or lateral position the
day before the scheduled surgery. USWE mode was activated
and prostate gland elastograms were obtained from cranial to
caudal direction for each lobe of the prostate. All regions were
scanned as described in our previous protocol (7). Briefly, each
patient’s prostate gland was scanned transrectally, and USWE
images were acquired in transverse planes from base to apex
with a gap of 4 to 6mm. The most suspicious lesions located
in planes were rescanned in gaps as thin as 2–3mm and
reconstructed oﬄine into 3-D images. These suspicious areas
were also examined by rotating transducers in different directions
to confirm abnormalities and to perform measurements of their
sizes. Three stiffness measurements of shear wave speed in m/s or
Young’s modulus in kPa using pseudo-color map were obtained
FIGURE 2 | Flowchart of study.
TABLE 2 | MRI acquisition parameters.
T1WI High-resolution T2WI DWI DCE
Axial Sagittal Axial Coronal DWI DWI high b value Dyn Gd-MRI
Sequence 2DTSE 2DTSE 2DTSE 2DTSE 2DEPI 2DEPI 3D VIBE
TR (ms) 650 6,000 4,000 5,000 3,300 3,300 4.76
TE (ms) 11 102 100 100 95 95 2.45
Flip angle (◦) 150 140 150 150 – – 10
Slice thickness (mm) 3 3 3 3 3 3 3
Slice gap (mm) 0.6 0.6 0.6 0.6 0 0 0.6
Resolution (pixels) 320 320 320 320 192 192 192
FOV (mm) 200 200 200 200 280 280 280
b values (s/mm2) – – – – 50, 100, 500, 1,000 2,000 –
Temporal resolution (s) – – – – – – 4
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FIGURE 3 | ROC curve of USWE (left) and PSAD (right) for differentiating BCR and BCR free of PCa after radical surgery.
TABLE 3 | Cox univariate and multivariate analyses.
Univariate Multivariate
HR (95% CI) P-value HR (95% CI) P-value
Preoperative parameters Age 1.000 (0.946–1.056) 0.991
Weight 0.990 (0.978–1.003) 0.119
SWE
≤144.85 1 (referent) – 1 (referent) –
>144.85 4.198 (2.036–8.653) <0.001 3.480 (1.654–7.322) 0.001
Gleason score at biopsy
≤7 1 (referent) – 1 (referent) –
>7 3.919 (2.119–7.248) <0.001 2.304 (1.207–4.398) 0.011
PSA level (ng/ml)
≤14.45 1 (referent) – 1 (referent) –
>14.45 2.954 (1.576–5.538) <0.001
PSAD (ng/ml2)
≤0.2237 1 (referent) – 1 (referent) –
>0.2237 2.820 (1.526–5.212) 0.001 2.405 (1.271–4.549) 0.007
PI-RADS
≤3 1 (referent) – 1 (referent) –
>3 2.856 (0.688–11.855) 0.148
Postoperative parameters Surgical margin
Neg 1 (referent) – 1 (referent) –
Pos 4.930 (2.468–9.848) <0.001 2.383 (1.136–4.999) 0.022
Vascular invasion
Neg 1 (referent) – 1 (referent) –
Pos 6.020 (2.914–12.434) <0.001 2.798 (1.236–6.333) 0.014
Gleason Score at RP
≤7 1 (referent) – 1 (referent) –
>7 11.293 (5.199–24.528) <0.001 6.518 (2.867–14.820) <0.001
Lymph node involvement
Neg 1 (referent) – 1 (referent) –
Pos 6.044 (2.652–13.775) <0.001 1.353 (0.528–3.467) 0.529
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by three researchers (GN, CW, and DU) independently. The ratio
between abnormal and normal areas was also recorded.
Statistical Analyses
In this paper, BCR as an outcome was a patient-based analysis
and hence major predominant and highest histological grade
was used. There could be multiple lesions for each patient and
lesion-based analysis has been published by our research group
previously (10, 11). Baseline characteristics and pathological
outcomes were compared using the chi-square test for categorical
data and the Student’s t-test or ANOVA for continuous data.
Receiver operator characteristic (ROC) curves were plotted for
stiffness values followed by application of maximum Youden
index (sensitivity–[1–specificity]), indicating that sensitivity and
specificity were equally important to determine optimal cutoff
values between BCR and BCR-free patients (14). Univariate and
multivariate Cox regression analyses were used to identify factors
predictive of BCR. Analyses were performed using SPSS 22 (IBM
Corporation, New York, USA). The alpha level was set at 0.05 to
determine two-tailed significance. The predicting outcome was
evaluated in nomograms and plotted in R 4.4.1. The values of
concordance indexes (C-index) were calculated and compared.
RESULTS
Of all 212 patients, 3 patients were excluded due to death from
other diseases during follow-up; the remaining 209 patients
eligible for final analysis including 2 patients with PCa-specific
deaths (treated as BCR patients) are illustrated in Figure 2. The
mean age of the cohort was 66 ± 4.95 years with a mean
preoperative PSA of 11.50 ± 7.63 ng/ml (range: 0.1–47.7). Of
all the eligible patients, 45 (45/209; 21.5%) experienced BCR
in an average of 26.3 ± 16.3 months (range: 3–66) during
their follow-up with 25 patients for salvage radiotherapy and 18
patients for hormones therapy. Almost a fifth of participants’
biopsy results were GS 6 (39/209, 18.7%), but only 5 (5/209;
2.4%) remained as GS 6 disease on histopathology of radical
prostatectomy, suggesting a significant upgrading of disease on
surgical resection (Table 1).
ROC curve was plotted and a cutoff value of 144.85 kPa
was calculated with the highest combination of sensitivity and
specificity, patients with BCR had 74.4% possibility of cancer
stiffness value above 144.85 kPa (sensitivity), and patients with
BCR free had a 61.7% possibility of cancer stiffness value
below 144.85 kPa (specificity, p < 0.05). The cutoff value
for preoperative PSAD level differentiating BCR and BCR-free
groups was 0.2237 ng/ml2 with a sensitivity and specificity of 46.3
and 80.1%, respectively (p < 0.05, Figure 3).
On univariate analysis, preoperative PSA level, PSAD, bGS,
and USWE were all significantly associated with BCR (p <
0.05). Age, weight, and mpMRI using PI-RADS v2 classification
without showing any significance (p > 0.05) were excluded
for further analyses. In the postoperative analysis, pGS was
significant in comparison to other parameters in predicting BCR
FIGURE 4 | Kaplan–Meier curves of BCR-free survival in four significant predictors: (A) ultrasound shear wave elastography (USWE); (B) surgical margin (SM); (C)
seminal vascular invasion (SVI); (D) pathology Gleason Score (pGS).
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with the highest hazard ratio (HR) of 11.293. Multivariable Cox
regression analysis showed the remaining variables excluding
LNI (p = 0.529) to be statistically significant and independently
predictive of BCR (p < 0.05, Table 3).
Figure 4 showed Kaplan–Meier survival analysis of BCR-
free survival for the four significant predictors including the
only preoperative parameter USWE and three postoperative
parameters: SM, SVI, and pGS.
FIGURE 5 | The nomograms of postoperative BCR prediction with (A1) and without USWE (A2). Calibration plots of actual and nomogram-predicted probability of
BCR with (B1) and without USWE (B2).
TABLE 4 | Literature review and comparison between previous and current studies.
Author Year Definition of BCR Recruitment Model Predictors C-index
Kattan et al.
(17, 18)
1998 PSA value of 0.4 ng/ml or greater 983 Preoperative PSA, bGS, clinical stage 0.79
1999 996 Postoperative PSA, pGS, SM, SVI, LNI 0.89
Grossfeld et al.
(21)
2003 2 consecutive PSA values over
0.2 ng/ml





2005 PSA value of 0.4 ng/ml or greater 1,782 Postoperative Validation 1 PSA, pGS, ECE, SM, SVI, LNI,
treatment years
0.81
1,357 Postoperative Validation 2 0.79
Cooperberg et al.
(19, 20)
2005 2 consecutive PSA values over
0.2 ng/ml
1,439 Preoperative PSA, bGS, clinical stage, age 0.66
2011 3,837 Postoperative PSA, pGS, SM, ECE, SVI, LNI 0.76
This study 2019 2 consecutive PSA values over
0.2 ng/ml
212 Without USWE PSA, GS, SM, SVI, LNI, USWE 0.702
With USWE 0.747
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Figures 5A1,A2 showed the nomograms constructed for BCR
with and without USWE data. Longer scales indicated a higher
percentage of impact and larger points were followed by shorter
BCR survival. The pGS had the greatest impact followed by
USWE and SVI. USWE was the only preoperative factor with
a significant impact on BCR-free survival. The C-index of the
established nomogram that had USWE variate to predict the
recurrence-free survival of patients in the cohort was significantly
higher than that of the nomogram without USWE {0.747 [95%
confidence interval (CI), 0.670–0.824] vs. 0.702 [95% CI, 0.625–
0.779], p < 0.05}. The nomograms were then internally validated
using 100 bootstrap samples; internal calibration curves were
shown in Figures 5B1,B2.
DISCUSSION
To our knowledge, this was the first report to predict BCR
with a non-histopathological independent imaging marker—
USWE. Clinical and histopathological variables on multivariate
analysis have all been previously reported. Introducing USWE
into nomograms for PCa BCR with other clinical, pathological,
and radiological parameters have increased the accuracy of BCR
prediction (0.747 vs. 0.702).
Previous published studies have reported USWE to have a
high diagnostic accuracy in clinical staging and localization
of tumors within prostate glands of men suspected of
PCa (6, 7, 10, 11, 15, 16). Our findings in this study add
to the existing knowledge and show that measurement
of stiffness in kPa increase BCR prediction ability of
clinicopathological parameters.
In this study, the USWE stiffness value was able to distinguish
BCR and BCR-free sub-cohort populations as shown in the first
ROC curve (Figure 3, left), and then using Youden analysis (14),
cancers’ stiffness cutoff value 144.85 kPa in Young’s modulus
was higher in our study in comparison to the number of other
reports in diagnosing cancer, but this was defined with the
highest combination of sensitivity and specificity, and a larger
number of high-grade cancers might have influenced this cutoff
value. In this study, we have then added this figure to other
clinical and histopathological biomarkers in nomograms for BCR
prediction (Figure 5).
Previous studies have analyzed the importance of preoperative
and postoperative data in predicting BCR. Kattan et al. (17, 18)
and Cooperberg et al. (19, 20) analyzed both data and found
that postoperative C-index values were higher than preoperative
values (0.89 vs. 0.79, 0.76 vs. 0.66). Grossfeld et al. (21) found
PSA levels, bGS, and percentage of biopsy cores involved by
cancer tissue to be significant preoperative predictors of BCR.
Stephenson et al. (22) validated two groups of patients and had
summarized similar postoperative C-index value (0.81 vs. 0.79).
Ozden et al. (23) recruited 305 patients and concluded that age
was not a significant factor to predict BRC, which was similar
to our study. Freedland et al. (24) found that the percentage
of biopsy cores involvement by cancer was a better predictor
than the number of cores involved by cancer. Similar to these
studies, in our observation, PSA and bGS were both significantly
important predictors of BCR. The definitions of BCR were
varied for different studies as shown in Table 4; this should be
considered when comparing results among different studies.
MRI characterization of PCa as the most advanced imaging
method has been assessed as a potential predictor of BCR as
well: Park et al. (25) concluded that PI-RADS might be useful
compared to other surgical parameters in 158 patients involved
in the study; Tan et al. (26) found that only MRI-detected tumor
volume was a significant predictor of BCR. Interestingly, and
similar to our findings, PI-RADS v2 was found to be statistically
insignificant on univariate analysis and was excluded from
further multivariable analysis. Despite its limited contribution
as a prognostic factor, mpMRI still remains a key role in PCa
detection, staging, and characterization (27, 28).
In the present series, PCa-specific mortality is very low
despite a relapse rate of 19% at a short median follow-up of
26.3 months. However, most biochemical relapses following
radical prostatectomy will take place within the first 24 months
of follow-up, and therefore, studies do give some window of
observation. Information from USWE-measured tissue stiffness
may potentially inform the decision to enroll patients with a high
risk of BCR into clinical trials after considering other factors
such as overall health and benefits of the interventions. Using
the current data in combination with other clinicopathological
factors, it is possible to identify patients at high risk of BCR
following prostatectomy, and these men may need an aggressive
approach using multimodality approach of combining hormones
and chemotherapy particularly when the latter has already shown
benefits in metastatic disease (29).
The current study has several limitations: firstly, this is a
single institutional study and needs to be externally validated; the
application of USWE in clinic still needs additional training and
appropriate literature to support it (30). Secondly, there aren’t
many patients involved with low-risk disease buy may require a
long follow-up to know biochemical outcomes. Lastly, as there
are a significant number of high-risk patients in this study, a
mean of 2 years of follow-up may cover the time period of early
biochemical failure in these men, but long-term follow-ups are
still needed.
Our findings in this study add to the existing knowledge
and show that USWE has the potential ability in a wide clinical
application field. This quantitative USWE imaging method may
optimize treatment decisions for patients with localized PCa.
Further studies are also needed to use this imaging method
in accurately selecting cancer patients for adjuvant treatment
following radical prostatectomy.
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